Media reports of a new CEO at Proctor & Gamble – People on the move
Robert McDonald is to be appointed as CEO of Proctor & Gamble (P&G), according to the Wall Street Journal, taking over from AG Lafley who is expected to stay on as chairman.
McDonald has worked at P&G for 29 years, currently as chief operating officer, and has been tipped to take the post when Lafley steps down. A board meeting is to be held later today.
AMAG Pharmaceuticals has appointed Ricardo Zayas as its senior vice president of operations. In this capacity Zayas will take responsibility for the company’s manufacturing, materials management, quality assurance, quality control and supply chain functions.
Zayas has over 20 years experience in pharmaceutical operations and commercial manufacturing at companies including Wyeth, Schering-Plough and Warner Lambert. At all three companies he worked in Puerto Rico.
Michael Valentino has been appointed as president and CEO of Xanodyne Pharmaceuticals, which also announced the completion of $38m (€27m) of equity financing.
Valentino most recently worked as CEO of Adams Respiratory Therapeutics and has over 30 years experience in the healthcare industry at companies including Alpharma, Novartis AG, Pharmacia/Upjohn and Warner Lambert.
As CEO of Adams Valentino completed an initial public offering (IPO) and later sold the company for $2.3bn.
Biopartners GmbH has appointed Conrad Savoy as its CEO and president. Savoy succeeds Jean-Noël Treilles who stepped down as CEO in March but will remain involved with the company in an advisory consultancy role.
The incoming CEO has worked at Biopartners since 2001 and has also held positions at Roche in his 18 years in the pharma and biotech industries.
